1010P Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study

• DOI: 10.1016/j.annonc.2020.08.1126
• Publication Date: 2020-09-22T08:49:28Z
• Authors: P. Merle; H.Y. Lim; R.S. Finn; M. Ikeda; M. Kudo; C. Frenette; G. Masi; Y.J. Kim; R. Gerolami; M. Kurosaki; K. Numata; H-J. Klümpen; H. Zebger-Gong; S. Fiala-Buskies; K. Ozgurdal; S. Qin
• Keywords: Regorafenib; Interim analysis; Liver function

International audience